UNSPSC 51442202: Gadobutrol

This classification denotes a gadolinium-chelate with the molecular formula C18H31N4O9.Gd, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1BJ477IO2L, chemically known as gadolinium, (10-(2,3-dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-n1,n4,n7,n10,o1,o4,o7)- but more generally known as gadobutrol, which bears U.S. National Institutes of Health Compound Identifier 72057.

UNSPSC 51442202 Gadobutrol is a Commodity code that, despite its nominal reference to a specific gadolinium-based magnetic resonance imaging contrast agent, shows little relevant recent activity tied to its abstract scope. The two most recent state and local opportunities tagged under this code involve unrelated procurement: Broward County Aviation Department issued an RFI on June 25, 2026 (responses due July 28, 2026) for maintenance services on Rapiscan X-ray inspection systems, and Pasco County, Florida posted an RFQ on June 3, 2026 (due June 26, 2026) for large copper sulfate crystals and liquid copper sulfate supplied on an as-needed basis. Neither opportunity involves gadobutrol or imaging contrast agents. The mismatch between the code's nominal scope and the actual work being solicited suggests that this code carries minimal relevance for vendors pursuing healthcare procurement contracts focused on diagnostic imaging supplies.

The geographic activity shown here spans Florida counties—Broward and Pasco—but the opportunities themselves fall outside the code's stated pharmaceutical or imaging-agent scope. No pattern of repeat buyers, established contract values, or multiple related solicitations emerges from the source material. Vendors evaluating this code should verify whether state and local procurement offices in their target jurisdictions are actually tagging contrast-agent procurement under this UNSPSC classification or whether it remains largely unused for its intended commodity category.